Identification of CYP isozymes involved in benzbromarone metabolism in human liver microsomes

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 8, 2012, Pages 466-473

  Kobayashi, Kaoru ^a   Kajiwara, Eri ^a   Ishikawa, Masayuki ^a   Oka, Hidenobu ^a   Chiba, Kan ^a,b  

^a CHIBA UNIVERSITY   (Japan)

^b Torii Nihonbashi Building   (Japan)

Author keywords

benzbromarone; human; liver microsomes; metabolism; P450

Indexed keywords

ALPHA NAPHTHOFLAVONE; BENZBROMARONE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLITE; PHENACETIN; TIENILIC ACID;

ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG METABOLISM; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME; LIVER MICROSOME METABOLISM;

BENZBROMARONE; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROXYLATION; ISOENZYMES; MICROSOMES, LIVER; RECOMBINANT PROTEINS; URICOSURIC AGENTS;

EID: 84867901984     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1813     Document Type: Article

References (17)

1. van der Klauw MM, Houtman PM, Stricker BH, Spoelstra P,. Hepatic injury caused by benzbromarone. J Hepatol 1994; 20: 376-379.
2. Arai M, Yokosuka O, Fujiwara K, et al,. Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol 2002; 17: 625-626.
3. Wagayama H, Shiraki K, Sugimoto K, et al,. Fatal fulminant hepatic failure associated with benzbromarone. J Hepatol 2000; 32: 874.
4. Suzuki T, Suzuki T, Kimura M, et al,. A case of fulminant hepatitis, possibly caused by benzbromarone. Nihon Shokakibyo Gakkai Zasshi 2001; 98: 421-425.
5. Jansen TL, Reinders MK, van Roon EN, Brouwers JR,. Benzbromarone withdrawn from the European market: another case of 'absence of evidence is evidence of absence'? Clin Exp Rheumatol 2004; 22: 651.
6. Lee MH, Graham GG, Williams KM, Day RO,. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf 2008; 31: 643-665.
7. Li AP,. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the 'multiple determinant hypothesis' for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 2002; 142: 7-23.
8. Broekhuysen J, Pacco M, Sion R, Demeulenaere L, Van Hee M,. Metabolism of benzbromarone in man. Eur J Clin Pharmacol 1972; 4: 125-130.
9. De Vries JX, Walter-Sack I, Ittensohn A, Weber E,. The isolation, identification and structure of a new hydroxylated metabolite of benzbromarone in man. Xenobiotica 1989; 19: 1461-1470.
10. McDonald MG, Rettie AE,. Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. Chem Res Toxicol 2007; 20: 1833-1842.
11. Iwamura A, Fukami T, Hosomi H, Nakajima M, Yokoi T,. CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. Drug Metab Dispos 2011; 39: 838-846.
12. Nomenclature Committee of the International Union of Biochemistry (NC-IUB). Symbolism and Terminology in Enzyme Kinetics, Recommendations 1981. Biochem J 1983; 213: 561-571.
13. Newton DJ, Wang RW, Lu AY,. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
14. Lõpez-Garcia MP, Dansette PM, Mansuy D,. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 1994; 33: 166-175.
15. Uchida S, Shimada K, Misaka S, et al,. Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes. Drug Metab Pharmacokinet 2010; 25: 605-610.
16. Kaufmann P, Török M, Hänni A, Roberts P, Gasser R, Krähenbühl S,. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 2005; 41: 925-935.
17. Walter-Sack I, de Vries JX, Ittensohn A, Weber E,. Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and metabolite profiles. Eur J Clin Pharmacol 1990; 39: 577-581.